Home > Publications Database > MRI phenotyping of underlying cerebral small vessel disease in mixed hemorrhage patients. > print

001     164283
005     20240304165424.0
024 7 _ |a 10.1016/j.jns.2020.117173
|2 doi
024 7 _ |a pmid:33068905
|2 pmid
024 7 _ |a 0022-510X
|2 ISSN
024 7 _ |a 1878-5883
|2 ISSN
024 7 _ |a altmetric:119283425
|2 altmetric
037 _ _ |a DZNE-2022-00937
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Scheumann, Vincent
|b 0
245 _ _ |a MRI phenotyping of underlying cerebral small vessel disease in mixed hemorrhage patients.
260 _ _ |a Amsterdam [u.a.]
|c 2020
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1709567618_22643
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a To investigate underlying cerebral small vessel disease (CSVD) in patients with mixed cerebral hemorrhages patterns and phenotype them according to the contribution of the two most common sporadic CSVD subtypes: cerebral amyloid angiopathy (CAA) vs. hypertensive arteriopathy (HA).Brain MRIs of patients with intracerebral hemorrhages (ICHs) and/or cerebral microbleeds (CMBs) were assessed for the full spectrum of CSVD markers using validated scales: ICHs, CMBs, cortical superficial siderosis (cSS), white matter hyperintensities, MRI-visible perivascular spaces (PVS). PVS predominance pattern was grouped as centrum-semiovale (CSO)-PVS predominance, basal-ganglia (BG)-PVS predominance, CSO-PVS and BG-PVS equality. Patients with mixed cerebral hemorrhages were classified into mixed CAA-pattern or mixed HA-pattern according to the existence of cSS and/or a CSO-PVS predominance pattern and comparisons were performed.We included 110 patients with CAA (strictly lobar ICHs/CMBs), 33 with HA (strictly deep ICHs/CMBs) and 97 with mixed lobar/deep ICHs/CMBs. Mixed patients were more similar to HA with respect to their MRI-CSVD markers, vascular risk profile and cerebrospinal fluid (CSF) measures. In the mixed patients, 33 (34%) had cSS, a CSO-PVS predominance pattern, or both, and were defined as mixed CAA-pattern cases. The mixed CAA-pattern patients were more alike CAA patients regarding their MRI-CSVD markers, CSF and genetic profile.Our findings suggest that the heterogeneous group of patients with mixed cerebral hemorrhages distribution can be further phenotyped according to the predominant underlying CSVD. cSS presence and a CSO-PVS predominance pattern could serve as strongly suggestive markers of a contribution from CAA among patients with mixed hemorrhages.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Cerebral amyloid angiopathy
|2 Other
650 _ 7 |a Cerebral small vessel diseases
|2 Other
650 _ 7 |a Cerebrospinal fluid
|2 Other
650 _ 7 |a Intracerebral hemorrhage
|2 Other
650 _ 7 |a MRI
|2 Other
650 _ 7 |a Vascular dementia
|2 Other
650 _ 2 |a Cerebral Amyloid Angiopathy
|2 MeSH
650 _ 2 |a Cerebral Hemorrhage: complications
|2 MeSH
650 _ 2 |a Cerebral Hemorrhage: diagnostic imaging
|2 MeSH
650 _ 2 |a Cerebral Small Vessel Diseases: complications
|2 MeSH
650 _ 2 |a Cerebral Small Vessel Diseases: diagnostic imaging
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Siderosis
|2 MeSH
700 1 _ |a Schreiber, Frank
|0 P:(DE-2719)9000986
|b 1
|u dzne
700 1 _ |a Perosa, Valentina
|0 P:(DE-2719)9000985
|b 2
|u dzne
700 1 _ |a Assmann, Anne
|0 P:(DE-2719)2812914
|b 3
|u dzne
700 1 _ |a Mawrin, Christian
|b 4
700 1 _ |a Garz, Cornelia
|0 P:(DE-2719)2813207
|b 5
|u dzne
700 1 _ |a Heinze, Hans-Jochen
|0 P:(DE-2719)2260426
|b 6
|u dzne
700 1 _ |a Görtler, Michael
|0 P:(DE-2719)2811292
|b 7
|u dzne
700 1 _ |a Düzel, Emrah
|0 P:(DE-2719)2000005
|b 8
|u dzne
700 1 _ |a Vielhaber, Stefan
|0 P:(DE-2719)2000035
|b 9
|u dzne
700 1 _ |a Charidimou, Andreas
|b 10
700 1 _ |a Schreiber, Stefanie
|0 P:(DE-2719)2812631
|b 11
|u dzne
773 _ _ |a 10.1016/j.jns.2020.117173
|g Vol. 419, p. 117173 -
|0 PERI:(DE-600)1500645-1
|p 117173
|t Journal of the neurological sciences
|v 419
|y 2020
|x 0022-510X
856 4 _ |u https://pub.dzne.de/record/164283/files/DZNE-2022-00937_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/164283/files/DZNE-2022-00937_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:164283
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9000986
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9000985
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 3
|6 P:(DE-2719)2812914
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2813207
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2260426
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 7
|6 P:(DE-2719)2811292
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2000005
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2000035
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2812631
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-26
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-26
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-08
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEUROL SCI : 2021
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-08
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-08
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-08
920 1 _ |0 I:(DE-2719)7000000
|k U Clinical Researchers - Magdeburg
|l U Clinical Researchers - Magdeburg
|x 0
920 1 _ |0 I:(DE-2719)5000006
|k AG Düzel
|l Clinical Neurophysiology and Memory
|x 1
920 1 _ |0 I:(DE-2719)1310005
|k AG Reymann
|l Pathophysiology of Dementia
|x 2
920 1 _ |0 I:(DE-2719)1310010
|k AG Schreiber
|l Mixed Cerebral Pathologies and Cognitive Aging
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)7000000
980 _ _ |a I:(DE-2719)5000006
980 _ _ |a I:(DE-2719)1310005
980 _ _ |a I:(DE-2719)1310010
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21